Rosiglitazone combined with insulin preserves islet ? cell function in LADA:A preliminary study
- VernacularTitle:罗格列酮与胰岛素合用对LADA患者胰岛?细胞功能保护作用的初步观察
- Author:
Xia LI
;
Zhiguang ZHOU
;
Gan HUANG
;
Al ET
;
- Publication Type:Journal Article
- Keywords:
Diabetes, autoimmune;
Thiazolidinediones;
Insulin;
Islet function;
Therapy
- From:Chinese Journal of Diabetes
1995;0(04):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of rosiglitazone and insulin on islet ? cell function in latent autoimmune diabetes in adults (LADA). Methods Glutamic acid decarboxylase (GAD) antibody was screened in patients initially diagnosed type 2 diabetes. LADA patients, defined as positive GAD antibody and with a fasting C peptide of 300 pmol/L or more, were selected and randomly assigned to receive subcutaneous insulin alone ( n =6) or rosiglitazone combined with insulin ( n =6) to compare the changes of islet ? cell function. At entry and 1 year after treatment, blood was drawn to determine plasma glucose, HbA 1c and C peptide at fasting and 2 hours after taking 75 g glucose without medication. GAD antibody and C peptide were measured with radioligand immunoassay and radioimmune assay respectively. Results After 1 year treatment, LADA patients in rosiglitazone and insulin group had a higher postprandial C peptide than those in subcutaneous insulin group(782.1 pmol/L vs 1 695.0 pmol/L, P
